The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
1
Chimeric antigen receptor T cells—CAR T cells for short—are immune cells (T cells) that are taken from the body and genetically modified outside the body in the laboratory using transport vehicles for the genes to be ...
Mar 22, 2024
0
0
Cytokines are chemical messengers that help the body get rid of invading bacteria and viruses, and control inflammation. The body carefully balances cytokines because they help keep the immune system healthy. However, this ...
Jan 17, 2024
0
54
Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers.
Sep 15, 2023
0
2
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ...
Jul 14, 2023
0
64
Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate, according to results ...
Apr 17, 2023
0
11
For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and ...
Feb 10, 2023
0
2
Results of an international clinical trial co-led by researchers at Winship Cancer Institute at Emory University show potential for a novel drug to benefit patients with multiple myeloma whose disease either recurred or was ...
Aug 3, 2022
0
1509
Axicabtagene ciloleucel (axi-cel; Yescarta) was approved for treatment of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy, the U.S. Food ...
Apr 15, 2022
0
3
Blood Cancer Discovery, a journal of the American Association for Cancer Research, has published a research article demonstrating a novel approach that may reduce a serious adverse effect associated with chimeric antigen ...
Dec 15, 2021
0
1
